Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 25 |
| List of Tables | 23 | 3 |
| List of Figures | 26 | 1 |
| Introduction | 27 | 1 |
| Global Markets Direct Report Coverage | 27 | 1 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview | 28 | 1 |
| Therapeutics Development | 29 | 2 |
| Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Overview | 29 | 1 |
| Pipeline Products for Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Comparative Analysis | 30 | 1 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics under Development by Companies | 31 | 7 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics under Investigation by Universities/Institutes | 38 | 2 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Pipeline Products Glance | 40 | 3 |
| Late Stage Products | 40 | 1 |
| Clinical Stage Products | 41 | 1 |
| Early Stage Products | 42 | 1 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Products under Development by Companies | 43 | 11 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Products under Investigation by Universities/Institutes | 54 | 2 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Companies Involved in Therapeutics Development | 56 | 90 |
| 4SC AG | 56 | 1 |
| Actinium Pharmaceuticals, Inc. | 57 | 1 |
| ADC Therapeutics SA | 58 | 1 |
| Affimed GmbH | 59 | 1 |
| Altor BioScience Corporation | 60 | 1 |
| Amgen Inc. | 61 | 1 |
| ARA Healthcare Pvt. Ltd. | 62 | 1 |
| Ariad Pharmaceuticals, Inc. | 63 | 1 |
| Array BioPharma Inc. | 64 | 1 |
| Atara Biotherapeutics, Inc. | 65 | 1 |
| Bellicum Pharmaceuticals, Inc. | 66 | 1 |
| Bexion Pharmaceuticals, LLC | 67 | 1 |
| Bio-Path Holdings, Inc. | 68 | 1 |
| BioSight Ltd. | 69 | 1 |
| Boehringer Ingelheim GmbH | 70 | 1 |
| Bristol-Myers Squibb Company | 71 | 1 |
| Calithera Biosciences, Inc. | 72 | 1 |
| Cantargia AB | 73 | 1 |
| Celgene Corporation | 74 | 1 |
| Cellectar Biosciences, Inc. | 75 | 1 |
| Cellectis S.A. | 76 | 1 |
| Cellular Biomedicine Group, Inc. | 77 | 1 |
| Ceronco Biosciences | 78 | 1 |
| Cielo Therapeutics Inc | 79 | 1 |
| Constellation Pharmaceuticals, Inc. | 80 | 1 |
| Cyclacel Pharmaceuticals, Inc. | 81 | 1 |
| Daiichi Sankyo Company, Limited | 82 | 1 |
| DiNonA Inc. | 83 | 1 |
| Eli Lilly and Company | 84 | 1 |
| EpiZyme, Inc. | 85 | 1 |
| Erytech Pharma SA | 86 | 1 |
| Eureka Therapeutics, Inc. | 87 | 1 |
| Fate Therapeutics, Inc. | 88 | 1 |
| Formula Pharmaceuticals, Inc. | 89 | 1 |
| Gamida Cell Ltd. | 90 | 1 |
| GlaxoSmithKline Plc | 91 | 1 |
| Hangzhou Minsheng Pharmaceutical Group Co.,Ltd | 92 | 1 |
| iDD biotech SAS | 93 | 1 |
| Immunomedics, Inc. | 94 | 1 |
| Incyte Corporation | 95 | 1 |
| Intech Biopharm Ltd | 96 | 1 |
| Interprotein Corporation | 97 | 1 |
| Jasco Pharmaceuticals, LLC. | 98 | 1 |
| Jazz Pharmaceuticals Plc | 99 | 1 |
| Johnson &Johnson | 100 | 1 |
| Juno Therapeutics Inc. | 101 | 1 |
| Karyopharm Therapeutics, Inc. | 102 | 1 |
| Kiadis Pharma N.V. | 103 | 1 |
| Kite Pharma Inc | 104 | 1 |
| Les Laboratoires Servier SAS | 105 | 1 |
| medac GmbH | 106 | 1 |
| Merck &Co., Inc. | 107 | 1 |
| Mesoblast Limited | 108 | 1 |
| Millennium Pharmaceuticals Inc | 109 | 1 |
| Moleculin Biotech Inc | 110 | 1 |
| Nanovalent Pharmaceuticals Inc. | 111 | 1 |
| Novartis AG | 112 | 1 |
| NovImmune SA | 113 | 1 |
| NuCana BioMed Limited | 114 | 1 |
| Omeros Corporation | 115 | 1 |
| OncoTartis, Inc. | 116 | 1 |
| OncoTherapy Science, Inc. | 117 | 1 |
| Oncternal Therapeutics, Inc. | 118 | 1 |
| Oribase Pharma | 119 | 1 |
| OSE Immunotherapeutics | 120 | 1 |
| Pfenex Inc. | 121 | 1 |
| Pfizer Inc. | 122 | 1 |
| Pharma Mar, S.A. | 123 | 1 |
| Portola Pharmaceuticals, Inc. | 124 | 1 |
| Red5 Pharmaceuticals, LLC | 125 | 1 |
| Regeneron Pharmaceuticals Inc | 126 | 1 |
| Sanofi | 127 | 1 |
| Sareum Holdings Plc | 128 | 1 |
| Seattle Genetics, Inc. | 129 | 1 |
| Sellas Inc | 130 | 1 |
| Shire Plc | 131 | 1 |
| Spectrum Pharmaceuticals, Inc. | 132 | 1 |
| Stemline Therapeutics, Inc. | 133 | 1 |
| SYNIMMUNE GmbH | 134 | 1 |
| Syros Pharmaceuticals Inc | 135 | 1 |
| Takeda Pharmaceutical Company Limited | 136 | 1 |
| TetraLogic Pharmaceuticals | 137 | 1 |
| Theravectys SA | 138 | 1 |
| Threshold Pharmaceuticals, Inc. | 139 | 1 |
| Tolero Pharmaceuticals, Inc. | 140 | 1 |
| Tragara Pharmaceuticals, Inc. | 141 | 1 |
| Verastem, Inc. | 142 | 1 |
| VioQuest Pharmaceuticals, Inc. | 143 | 1 |
| Xbrane Biopharma AB | 144 | 1 |
| ZIOPHARM Oncology, Inc. | 145 | 1 |
| Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) Therapeutics Assessment | 146 | 22 |
| Assessment by Monotherapy Products | 146 | 1 |
| Assessment by Combination Products | 147 | 1 |
| Assessment by Target | 148 | 8 |
| Assessment by Mechanism of Action | 156 | 8 |
| Assessment by Route of Administration | 164 | 2 |
| Assessment by Molecule Type | 166 | 2 |
| Drug Profiles | 168 | 494 |
| (cytarabine hydrochloride + daunorubicin hydrochloride) Drug Profile | 168 | 11 |
| 4-G7SDIE Drug Profile | 179 | 1 |
| 4SC-202 Drug Profile | 180 | 2 |
| ABL-001 Drug Profile | 182 | 1 |
| ADCT-301 Drug Profile | 183 | 2 |
| ADCT-402 Drug Profile | 185 | 2 |
| AFM-11 Drug Profile | 187 | 1 |
| ALT-803 Drug Profile | 188 | 3 |
| Annamycin Drug Profile | 191 | 2 |
| APX-3330 Drug Profile | 193 | 2 |
| ARABS-1 Drug Profile | 195 | 1 |
| asparaginase Drug Profile | 196 | 7 |
| asparaginase Drug Profile | 203 | 1 |
| ATIR-101 Drug Profile | 204 | 4 |
| AVR-01 Drug Profile | 208 | 1 |
| BC-8SA Drug Profile | 209 | 1 |
| BC-8Y90 Drug Profile | 210 | 1 |
| binimetinib Drug Profile | 211 | 7 |
| birabresib Drug Profile | 218 | 2 |
| birinapant Drug Profile | 220 | 7 |
| blinatumomab Drug Profile | 227 | 8 |
| BLyS-gel Drug Profile | 235 | 1 |
| BMS-871 Drug Profile | 236 | 1 |
| BMS-906024 Drug Profile | 237 | 2 |
| bortezomib Drug Profile | 239 | 8 |
| bosutinib Drug Profile | 247 | 5 |
| BP-1001 Drug Profile | 252 | 7 |
| BPX-401 Drug Profile | 259 | 2 |
| brentuximab vedotin Drug Profile | 261 | 22 |
| BSK-01 Drug Profile | 283 | 1 |
| BST-236 Drug Profile | 284 | 1 |
| buparlisib hydrochloride Drug Profile | 285 | 5 |
| BXQ-350 Drug Profile | 290 | 2 |
| C-15231A Drug Profile | 292 | 1 |
| calaspargase pegol Drug Profile | 293 | 1 |
| CAN-04 Drug Profile | 294 | 3 |
| carfilzomib Drug Profile | 297 | 12 |
| CB-839 Drug Profile | 309 | 7 |
| CBM-C19.1 Drug Profile | 316 | 1 |
| CBM-C20.1 Drug Profile | 317 | 2 |
| CD19L-sTRAIL Drug Profile | 319 | 1 |
| Cellular Immunotherapy for Acute Lymphoblastic Leukemia Drug Profile | 320 | 1 |
| Cellular Immunotherapy for B-cell Malignancies Drug Profile | 321 | 1 |
| Cellular Immunotherapy for Hematological Malignancies Drug Profile | 322 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 323 | 1 |
| Cellular Immunotherapy for Oncology Drug Profile | 324 | 1 |
| Cellular Immunotherapy to Activate IL-12 and to Target CD19 for B-Cell Malignancies Drug Profile | 325 | 2 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphoblastic Leukemia Drug Profile | 327 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphoblastic Leukemia Drug Profile | 328 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphoblastic Leukemia Drug Profile | 329 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphocytic Leukemia and Diffuse Large B-Cell Lymphoma Drug Profile | 330 | 1 |
| Cellular Immunotherapy to Target CD19 for Acute Lymphocytic Leukemia and Non-Hodgkin Lymphoma Drug Profile | 331 | 1 |
| Cellular Immunotherapy to Target CD19 for ALL Drug Profile | 332 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Leukemias and B-Cell Lymphomas Drug Profile | 333 | 1 |
| Cellular Immunotherapy to Target CD19 for B-Cell Malignancies Drug Profile | 334 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 335 | 1 |
| Cellular Immunotherapy to Target CD19 for Oncology Drug Profile | 336 | 1 |
| Cellular Immunotherapy to Target CD22 for Acute Lymphoblastic Leukemia Drug Profile | 337 | 1 |
| Cellular Immunotherapy to Target CD25 and CD71 for Acute Lymphocytic Leukemia and Acute Myelocytic Leukemia Drug Profile | 338 | 1 |
| Cellular Immunotherapy to Target TSLPR for Acute Lymphoblastic Leukemia Drug Profile | 339 | 1 |
| Cellular Immunotherapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology Drug Profile | 340 | 1 |
| Cellular Immunotherapy to Target WT1 for Oncology Drug Profile | 341 | 2 |
| CHZ-868 Drug Profile | 343 | 1 |
| CM-272 Drug Profile | 344 | 1 |
| CPI-0610 Drug Profile | 345 | 2 |
| CSG-CD19 Drug Profile | 347 | 1 |
| CY-190602 Drug Profile | 348 | 1 |
| CYC-065 Drug Profile | 349 | 3 |
| danusertib Drug Profile | 352 | 1 |
| daratumumab Drug Profile | 353 | 11 |
| denintuzumab mafodotin Drug Profile | 364 | 3 |
| DFP-10917 Drug Profile | 367 | 1 |
| DNP-001 Drug Profile | 368 | 1 |
| Drug to Target CD22 for B-Precursor Acute Lymphoblastic Leukemia Drug Profile | 369 | 1 |
| Drugs to Target NT5C2 for Relapsing Acute Lymphoblastic Leukemia Drug Profile | 370 | 1 |
| DS-3032 Drug Profile | 371 | 1 |
| DT-1154 Drug Profile | 372 | 1 |
| EFFI-7H Drug Profile | 373 | 2 |
| epratuzumab Drug Profile | 375 | 7 |
| ESK-1 Drug Profile | 382 | 2 |
| ESK-BiTE Drug Profile | 384 | 1 |
| everolimus Drug Profile | 385 | 13 |
| galinpepimut-S Drug Profile | 398 | 3 |
| glasdegib Drug Profile | 401 | 2 |
| GSKJ-4 Drug Profile | 403 | 1 |
| HDM-201 Drug Profile | 404 | 1 |
| HSC-835 Drug Profile | 405 | 1 |
| huCART19 Drug Profile | 406 | 1 |
| I131-CLR1404 Drug Profile | 407 | 4 |
| ICG-128 Drug Profile | 411 | 1 |
| ICG-129 Drug Profile | 412 | 1 |
| IDD-001 Drug Profile | 413 | 1 |
| IDD-002 Drug Profile | 414 | 1 |
| IMMU-114 Drug Profile | 415 | 2 |
| inotuzumab ozogamicin Drug Profile | 417 | 4 |
| Iomab-B Drug Profile | 421 | 5 |
| IPC-003 Drug Profile | 426 | 1 |
| isatuximab Drug Profile | 427 | 2 |
| ixazomib citrate Drug Profile | 429 | 10 |
| J-9 Drug Profile | 439 | 1 |
| JCAR-014 Drug Profile | 440 | 3 |
| JCAR-015 Drug Profile | 443 | 4 |
| JCAR-017 Drug Profile | 447 | 3 |
| JCAR-018 Drug Profile | 450 | 2 |
| JCAR-024 Drug Profile | 452 | 1 |
| JNJ-64052781 Drug Profile | 453 | 2 |
| JP-11646 Drug Profile | 455 | 1 |
| KPC-34 Drug Profile | 456 | 1 |
| KPT-251 Drug Profile | 457 | 1 |
| KPT-8602 Drug Profile | 458 | 2 |
| KTEC-19 Drug Profile | 460 | 8 |
| lenaldekar Drug Profile | 468 | 1 |
| lurbinectedin Drug Profile | 469 | 7 |
| LY-3039478 Drug Profile | 476 | 1 |
| mercaptopurine Drug Profile | 477 | 1 |
| methotrexate Drug Profile | 478 | 1 |
| methotrexate Drug Profile | 479 | 1 |
| methotrexate Drug Profile | 480 | 1 |
| mitoxantrone hydrochloride Drug Profile | 481 | 1 |
| Monoclonal Antibody to Inhibit BAFF-R for B Acute Lymphoblastic Leukemia Drug Profile | 482 | 1 |
| Monoclonal Antibody to Target CD66b for Blood Cancer and Metabolic Disorders Drug Profile | 483 | 1 |
| Monocloncal Antibody to Target CD-19 for Oncology Drug Profile | 484 | 1 |
| MPC-CBE Drug Profile | 485 | 2 |
| MRX-2843 Drug Profile | 487 | 1 |
| MRX-6313 Drug Profile | 488 | 1 |
| MSK-777 Drug Profile | 489 | 1 |
| MTR-393 Drug Profile | 490 | 1 |
| NI-1701 Drug Profile | 491 | 1 |
| NiCord Drug Profile | 492 | 3 |
| nilotinib Drug Profile | 495 | 6 |
| NM-814 Drug Profile | 501 | 1 |
| NM-869 Drug Profile | 502 | 1 |
| NUC-5435 Drug Profile | 503 | 1 |
| NV-102 Drug Profile | 504 | 1 |